BRAF and Ehlers-Danlos syndrome, musculocontractural type: Whether the combination of lenvatinib and pembrolizumab is a valid treatment option in patients with BRAF-mutated ATCs remains unclear: while we found transient activity in both patients, a lower objective response rate to the PD-1 inhibitor spartalizumab has previously been demonstrated in ATC patients with BRAF V600E mutation [7].